Last reviewed · How we verify
Duo-Therapy with Sildenafil + Bosentan
This combination therapy dilates pulmonary blood vessels through dual inhibition of phosphodiesterase-5 and endothelin-1 receptor signaling.
This combination therapy dilates pulmonary blood vessels through dual inhibition of phosphodiesterase-5 and endothelin-1 receptor signaling. Used for Pulmonary arterial hypertension.
At a glance
| Generic name | Duo-Therapy with Sildenafil + Bosentan |
|---|---|
| Also known as | Dual therapy with Revatio and Tracleer |
| Sponsor | Johns Hopkins University |
| Drug class | Combination therapy: phosphodiesterase-5 inhibitor + endothelin receptor antagonist |
| Target | PDE-5; Endothelin receptor A and B |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Sildenafil inhibits phosphodiesterase-5, increasing cyclic GMP and promoting vasodilation. Bosentan is an endothelin receptor antagonist that blocks vasoconstriction mediated by endothelin-1. Together, these agents work synergistically to reduce pulmonary vascular resistance and improve hemodynamics in pulmonary hypertension.
Approved indications
- Pulmonary arterial hypertension
Common side effects
- Headache
- Flushing
- Dyspepsia
- Liver enzyme elevation
- Fluid retention
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: